Royal London Asset Management’s Emergent Biosolutions EBS Stock Holding History

Royal London Asset Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$901K	Buy	+32,059	New	+$1.26M	0.01%	517

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal London Asset Management's EBS Position: Q2 2016 in Review

Royal London Asset Management opened a new position in Emergent Biosolutions (EBS) in Q2 2016: 32,059 shares worth $901K. The stake represents 0.01% of the portfolio and ranks #517 among its holdings.

224 funds tracked by Wall St. Rank hold EBS as of Q2 2016.

Royal London Asset Management held 32,059 shares of Emergent Biosolutions worth $901K as of Q2 2016.
Emergent Biosolutions was a new Royal London Asset Management position in Q2 2016.
Emergent Biosolutions made up 0.01% of Royal London Asset Management's portfolio in Q2 2016, its #517 holding.
224 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2016.

Based on Royal London Asset Management's 13F filing for Q2 2016, filed 2 Aug 2016.